Akari Therapeutics Announces First Patient to Complete Course of Treatment in the Phase III Part A Clinical Trial of Investigational Nomacopan in Pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA)
NEW YORK and LONDON, July 07, 2022 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company focused on developing advanced therapies for autoimmune and inflammatory diseases, today announced that a patient has completed the course of investigational nomacopan treatment in the open-label, multi-center Phase III Part A clinical trial in pediatric hematopoietic stem cell transplant-related […]
“New Treatments for Age-Related Macular Degeneration: Drug, Genes & Stem Cells”-Dr. Marco Zarbin
The invited speaker at the July 5, 2022 meeting of the Old Guard of Summit NJ was Dr. Marco Zarbin who discussed how age-related macular degeneration (AMD) is the leading cause of blindness among persons over 55, and the range of new treatments that are available and coming in the near future. Thirty percent of […]
Stem Cell Therapy – Miracles and Money Wasted
Stem cells have an amazing ability to repair tissue damage. They seem to improve many conditions including Alzheimer’s, arthritis, cardiac disease and much more. But, that potential is luring consumers to spend big money on unproven treatments. HealthCall’s Lee Kelso explores this problem and the potential of stem cell therapy with Dr. Ernst Von Schwarz, […]
ISSCR 2022: On the Ground | The Stem Cell Podcast
In this special episode of the Stem Cell Podcast, Daylon and Arun talk with delegates at the ISSCR 2022 annual meeting. The attendees discuss the memorable research presented and share their thoughts on the challenges facing the stem cell field.
Inceptor Bio Announces Strategic Collaboration with University of Minnesota to Develop Novel iPSC Platform for the Advancement of Next-Generation Allogeneic Cell Therapies
MORRISVILLE, N.C., June 30, 2022 /PRNewswire/ — Inceptor Bio, a biotechnology company advancing cell therapies for difficult-to-treat cancers, today announced a collaboration with University of Minnesota. The aim of this collaboration is to build a novel induced pluripotent stem cells (iPSC) platform that will accelerate Inceptor Bio’s best-in-class next-generation cell therapies platforms. Under the terms of […]
The 2022 Ogawa-Yamanaka Stem Cell Prize Awarded to Juan Carlos Izpisua Belmonte
SAN FRANCISCO, June 28, 2022 /PRNewswire/ — Juan Carlos Izpisua Belmonte, PhD, was announced today as the recipient of the 2022 Ogawa-Yamanaka Stem Cell Prize by Gladstone Institutes. Izpisua Belmonte is director of the San Diego Institute of Science of Altos Labs, a new life sciences company focused on restoring cell health and resilience through […]
Animal Stem Cell Therapy Market projected CAGR of 5.2% for the next ten years (2022-2032) – Persistence Market Research
New York, June 27, 2022 (GLOBE NEWSWIRE) — The global animal stem cell therapy market recorded sales of around US$ 249.9 Mn in 2021 and the market is predicted to experience healthy growth over the years ahead at a CAGR of 5.2% (2022 to 2032). Animal stem cell therapies are treatments for disorders such as […]
Can Stem Cells Activate Tooth Regeneration?
A genetic variation in dental pulp stem cells enables continuous regeneration, enabling them to restore teeth from within. Video Transcript: Hi, Madina here and welcome back to Stem Cell Talks. Today we want to talk about a groundbreaking new study where researchers discovered a new property of dental pulp stem cells also known as DPSCs. […]
Hear How Stem Cell Treatments for Autism Changed Daughter’s Life
Gina and Wade join The Doctors to share about how their daughter Gracie reacted to stem cell treatment for autism in the Duke University study. Video Transcript: – Let’s bring parents, Gina and Wade into the discussion now, whose daughter was part of the same clinical trial at Duke, but had a totally different experience. […]
Vor Bio Successfully Demonstrates Multiplex Editing of Hematopoietic Stem Cells for Next-generation AML Treatment Presented at EHA
CAMBRIDGE, Mass., June 10, 2022 (GLOBE NEWSWIRE) — Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced successful first of its kind dual editing of CD33 and CLL-1 in human hematopoietic stem cells (HSCs) demonstrating continued progress on its novel approach for the treatment of acute myeloid leukemia (AML). The data […]